Loading…

Effective screening of SARS-CoV-2 neutralizing antibodies in patient serum using lentivirus particles pseudotyped with SARS-CoV-2 spike glycoprotein

Pseuodotyped particles have significant importance and use in virology as tools for studying the biology of highly pathogenic viruses in a lower biosafety environment. The biological, chemical, and serological studies of the recently emerged SARS-CoV-2 will be greatly aided by the development and op...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2020-11, Vol.10 (1), p.19076-19076, Article 19076
Main Authors: Tandon, Ritesh, Mitra, Dipanwita, Sharma, Poonam, McCandless, Martin G., Stray, Stephen J., Bates, John T., Marshall, Gailen D.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c474t-1b2f2a8cded559074e4c991ed0a4f96627ef51eb0a17bbeadc7511289c3be78c3
cites cdi_FETCH-LOGICAL-c474t-1b2f2a8cded559074e4c991ed0a4f96627ef51eb0a17bbeadc7511289c3be78c3
container_end_page 19076
container_issue 1
container_start_page 19076
container_title Scientific reports
container_volume 10
creator Tandon, Ritesh
Mitra, Dipanwita
Sharma, Poonam
McCandless, Martin G.
Stray, Stephen J.
Bates, John T.
Marshall, Gailen D.
description Pseuodotyped particles have significant importance and use in virology as tools for studying the biology of highly pathogenic viruses in a lower biosafety environment. The biological, chemical, and serological studies of the recently emerged SARS-CoV-2 will be greatly aided by the development and optimization of a suitable pseudotyping system. Here, we pseudotyped the SARS-CoV-2 Spike glycoprotein (SPG) on a traditional retroviral (MMLV) as well as a third generation lentiviral (pLV) vector and tested the transduction efficiency in several mammalian cell lines expressing SARS-CoV-2 receptor hACE2. While MMLV pseudotyped the vesicular stomatitis virus G glycoprotein (VSV-G) efficiently, it could not pseudotype the full-length SPG. In contrast, pLV pseudotyped both glycoproteins efficiently; however, much higher titers of pLV-G particles were produced. Among all the tested mammalian cells, 293Ts expressing hACE2 were most efficiently transduced using the pLV-S system. The pLV-S particles were efficiently neutralized by diluted serum (>:640) from recently recovered COVID-19 patients who showed high SARS-CoV-2 specific IgM and IgG levels. In summary, pLV-S pseudotyped virus provides a valid screening tool for the presence of anti SARS-CoV-2 specific neutralizing antibodies in convalescent patient serum.
doi_str_mv 10.1038/s41598-020-76135-w
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7645753</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2458039211</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-1b2f2a8cded559074e4c991ed0a4f96627ef51eb0a17bbeadc7511289c3be78c3</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhSMEolXpC7BAltiwCfg3jjdI1aj8SJUq0cLWcpybqUvGDrYzo-E5eGA8TGkHFvXGls93z71Xp6peEvyWYNa-S5wI1daY4lo2hIl686Q6ppiLmjJKnx68j6rTlG5xOYIqTtTz6ogxIrgg_Lj6dT4MYLNbA0o2AnjnlygM6Orsy1W9CN9qijzMOZrR_dxJxmfXhd5BQs6jyWQHPqMEcV6hOe2IsXy4tYtzKnLMzo6FnRLMfcjbCXq0cfnm0D9N7jug5bi1YYohg_MvqmeDGROc3t0n1dcP59eLT_XF5cfPi7OL2nLJc006OlDT2h56IRSWHLhVikCPDR9U01AJgyDQYUNk14HprRSE0FZZ1oFsLTup3u99p7lbQW_L5GVRPUW3MnGrg3H6X8W7G70May0bLqRgxeDNnUEMP2ZIWa9csjCOxkOYk6ZctJgpSkhBX_-H3oY5-rJeoWSJAzeNKBTdUzaGlCIM98MQrHe5633uuuSu_-SuN6Xo1eEa9yV_Uy4A2wOpSH4J8aH3I7a_AaRuvNI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2471540665</pqid></control><display><type>article</type><title>Effective screening of SARS-CoV-2 neutralizing antibodies in patient serum using lentivirus particles pseudotyped with SARS-CoV-2 spike glycoprotein</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><source>Free Full-Text Journals in Chemistry</source><source>Coronavirus Research Database</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Tandon, Ritesh ; Mitra, Dipanwita ; Sharma, Poonam ; McCandless, Martin G. ; Stray, Stephen J. ; Bates, John T. ; Marshall, Gailen D.</creator><creatorcontrib>Tandon, Ritesh ; Mitra, Dipanwita ; Sharma, Poonam ; McCandless, Martin G. ; Stray, Stephen J. ; Bates, John T. ; Marshall, Gailen D.</creatorcontrib><description>Pseuodotyped particles have significant importance and use in virology as tools for studying the biology of highly pathogenic viruses in a lower biosafety environment. The biological, chemical, and serological studies of the recently emerged SARS-CoV-2 will be greatly aided by the development and optimization of a suitable pseudotyping system. Here, we pseudotyped the SARS-CoV-2 Spike glycoprotein (SPG) on a traditional retroviral (MMLV) as well as a third generation lentiviral (pLV) vector and tested the transduction efficiency in several mammalian cell lines expressing SARS-CoV-2 receptor hACE2. While MMLV pseudotyped the vesicular stomatitis virus G glycoprotein (VSV-G) efficiently, it could not pseudotype the full-length SPG. In contrast, pLV pseudotyped both glycoproteins efficiently; however, much higher titers of pLV-G particles were produced. Among all the tested mammalian cells, 293Ts expressing hACE2 were most efficiently transduced using the pLV-S system. The pLV-S particles were efficiently neutralized by diluted serum (&gt;:640) from recently recovered COVID-19 patients who showed high SARS-CoV-2 specific IgM and IgG levels. In summary, pLV-S pseudotyped virus provides a valid screening tool for the presence of anti SARS-CoV-2 specific neutralizing antibodies in convalescent patient serum.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-020-76135-w</identifier><identifier>PMID: 33154514</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/326 ; 631/326/596 ; 692/308/2778 ; Animals ; Antibodies, Neutralizing - blood ; Antibodies, Neutralizing - immunology ; Antibodies, Viral - blood ; Antibodies, Viral - immunology ; Betacoronavirus - immunology ; Cell Line ; Cell lines ; COVID-19 ; Genetic Vectors - genetics ; Glycoproteins ; Humanities and Social Sciences ; Humans ; Immunoglobulin G ; Immunoglobulin M ; Lentivirus - genetics ; Mammalian cells ; multidisciplinary ; SARS-CoV-2 ; Science ; Science (multidisciplinary) ; Serologic Tests - methods ; Severe acute respiratory syndrome coronavirus 2 ; Spike glycoprotein ; Spike Glycoprotein, Coronavirus - genetics ; Spike Glycoprotein, Coronavirus - immunology ; Stomatitis ; Transduction, Genetic</subject><ispartof>Scientific reports, 2020-11, Vol.10 (1), p.19076-19076, Article 19076</ispartof><rights>The Author(s) 2020</rights><rights>The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-1b2f2a8cded559074e4c991ed0a4f96627ef51eb0a17bbeadc7511289c3be78c3</citedby><cites>FETCH-LOGICAL-c474t-1b2f2a8cded559074e4c991ed0a4f96627ef51eb0a17bbeadc7511289c3be78c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2471540665/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2471540665?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,38516,43895,44590,53791,53793,74412,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33154514$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tandon, Ritesh</creatorcontrib><creatorcontrib>Mitra, Dipanwita</creatorcontrib><creatorcontrib>Sharma, Poonam</creatorcontrib><creatorcontrib>McCandless, Martin G.</creatorcontrib><creatorcontrib>Stray, Stephen J.</creatorcontrib><creatorcontrib>Bates, John T.</creatorcontrib><creatorcontrib>Marshall, Gailen D.</creatorcontrib><title>Effective screening of SARS-CoV-2 neutralizing antibodies in patient serum using lentivirus particles pseudotyped with SARS-CoV-2 spike glycoprotein</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>Pseuodotyped particles have significant importance and use in virology as tools for studying the biology of highly pathogenic viruses in a lower biosafety environment. The biological, chemical, and serological studies of the recently emerged SARS-CoV-2 will be greatly aided by the development and optimization of a suitable pseudotyping system. Here, we pseudotyped the SARS-CoV-2 Spike glycoprotein (SPG) on a traditional retroviral (MMLV) as well as a third generation lentiviral (pLV) vector and tested the transduction efficiency in several mammalian cell lines expressing SARS-CoV-2 receptor hACE2. While MMLV pseudotyped the vesicular stomatitis virus G glycoprotein (VSV-G) efficiently, it could not pseudotype the full-length SPG. In contrast, pLV pseudotyped both glycoproteins efficiently; however, much higher titers of pLV-G particles were produced. Among all the tested mammalian cells, 293Ts expressing hACE2 were most efficiently transduced using the pLV-S system. The pLV-S particles were efficiently neutralized by diluted serum (&gt;:640) from recently recovered COVID-19 patients who showed high SARS-CoV-2 specific IgM and IgG levels. In summary, pLV-S pseudotyped virus provides a valid screening tool for the presence of anti SARS-CoV-2 specific neutralizing antibodies in convalescent patient serum.</description><subject>631/326</subject><subject>631/326/596</subject><subject>692/308/2778</subject><subject>Animals</subject><subject>Antibodies, Neutralizing - blood</subject><subject>Antibodies, Neutralizing - immunology</subject><subject>Antibodies, Viral - blood</subject><subject>Antibodies, Viral - immunology</subject><subject>Betacoronavirus - immunology</subject><subject>Cell Line</subject><subject>Cell lines</subject><subject>COVID-19</subject><subject>Genetic Vectors - genetics</subject><subject>Glycoproteins</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Immunoglobulin G</subject><subject>Immunoglobulin M</subject><subject>Lentivirus - genetics</subject><subject>Mammalian cells</subject><subject>multidisciplinary</subject><subject>SARS-CoV-2</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>Serologic Tests - methods</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Spike glycoprotein</subject><subject>Spike Glycoprotein, Coronavirus - genetics</subject><subject>Spike Glycoprotein, Coronavirus - immunology</subject><subject>Stomatitis</subject><subject>Transduction, Genetic</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><recordid>eNp9kc1u1DAUhSMEolXpC7BAltiwCfg3jjdI1aj8SJUq0cLWcpybqUvGDrYzo-E5eGA8TGkHFvXGls93z71Xp6peEvyWYNa-S5wI1daY4lo2hIl686Q6ppiLmjJKnx68j6rTlG5xOYIqTtTz6ogxIrgg_Lj6dT4MYLNbA0o2AnjnlygM6Orsy1W9CN9qijzMOZrR_dxJxmfXhd5BQs6jyWQHPqMEcV6hOe2IsXy4tYtzKnLMzo6FnRLMfcjbCXq0cfnm0D9N7jug5bi1YYohg_MvqmeDGROc3t0n1dcP59eLT_XF5cfPi7OL2nLJc006OlDT2h56IRSWHLhVikCPDR9U01AJgyDQYUNk14HprRSE0FZZ1oFsLTup3u99p7lbQW_L5GVRPUW3MnGrg3H6X8W7G70May0bLqRgxeDNnUEMP2ZIWa9csjCOxkOYk6ZctJgpSkhBX_-H3oY5-rJeoWSJAzeNKBTdUzaGlCIM98MQrHe5633uuuSu_-SuN6Xo1eEa9yV_Uy4A2wOpSH4J8aH3I7a_AaRuvNI</recordid><startdate>20201105</startdate><enddate>20201105</enddate><creator>Tandon, Ritesh</creator><creator>Mitra, Dipanwita</creator><creator>Sharma, Poonam</creator><creator>McCandless, Martin G.</creator><creator>Stray, Stephen J.</creator><creator>Bates, John T.</creator><creator>Marshall, Gailen D.</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20201105</creationdate><title>Effective screening of SARS-CoV-2 neutralizing antibodies in patient serum using lentivirus particles pseudotyped with SARS-CoV-2 spike glycoprotein</title><author>Tandon, Ritesh ; Mitra, Dipanwita ; Sharma, Poonam ; McCandless, Martin G. ; Stray, Stephen J. ; Bates, John T. ; Marshall, Gailen D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-1b2f2a8cded559074e4c991ed0a4f96627ef51eb0a17bbeadc7511289c3be78c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>631/326</topic><topic>631/326/596</topic><topic>692/308/2778</topic><topic>Animals</topic><topic>Antibodies, Neutralizing - blood</topic><topic>Antibodies, Neutralizing - immunology</topic><topic>Antibodies, Viral - blood</topic><topic>Antibodies, Viral - immunology</topic><topic>Betacoronavirus - immunology</topic><topic>Cell Line</topic><topic>Cell lines</topic><topic>COVID-19</topic><topic>Genetic Vectors - genetics</topic><topic>Glycoproteins</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Immunoglobulin G</topic><topic>Immunoglobulin M</topic><topic>Lentivirus - genetics</topic><topic>Mammalian cells</topic><topic>multidisciplinary</topic><topic>SARS-CoV-2</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>Serologic Tests - methods</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Spike glycoprotein</topic><topic>Spike Glycoprotein, Coronavirus - genetics</topic><topic>Spike Glycoprotein, Coronavirus - immunology</topic><topic>Stomatitis</topic><topic>Transduction, Genetic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tandon, Ritesh</creatorcontrib><creatorcontrib>Mitra, Dipanwita</creatorcontrib><creatorcontrib>Sharma, Poonam</creatorcontrib><creatorcontrib>McCandless, Martin G.</creatorcontrib><creatorcontrib>Stray, Stephen J.</creatorcontrib><creatorcontrib>Bates, John T.</creatorcontrib><creatorcontrib>Marshall, Gailen D.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Science Journals</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tandon, Ritesh</au><au>Mitra, Dipanwita</au><au>Sharma, Poonam</au><au>McCandless, Martin G.</au><au>Stray, Stephen J.</au><au>Bates, John T.</au><au>Marshall, Gailen D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effective screening of SARS-CoV-2 neutralizing antibodies in patient serum using lentivirus particles pseudotyped with SARS-CoV-2 spike glycoprotein</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2020-11-05</date><risdate>2020</risdate><volume>10</volume><issue>1</issue><spage>19076</spage><epage>19076</epage><pages>19076-19076</pages><artnum>19076</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>Pseuodotyped particles have significant importance and use in virology as tools for studying the biology of highly pathogenic viruses in a lower biosafety environment. The biological, chemical, and serological studies of the recently emerged SARS-CoV-2 will be greatly aided by the development and optimization of a suitable pseudotyping system. Here, we pseudotyped the SARS-CoV-2 Spike glycoprotein (SPG) on a traditional retroviral (MMLV) as well as a third generation lentiviral (pLV) vector and tested the transduction efficiency in several mammalian cell lines expressing SARS-CoV-2 receptor hACE2. While MMLV pseudotyped the vesicular stomatitis virus G glycoprotein (VSV-G) efficiently, it could not pseudotype the full-length SPG. In contrast, pLV pseudotyped both glycoproteins efficiently; however, much higher titers of pLV-G particles were produced. Among all the tested mammalian cells, 293Ts expressing hACE2 were most efficiently transduced using the pLV-S system. The pLV-S particles were efficiently neutralized by diluted serum (&gt;:640) from recently recovered COVID-19 patients who showed high SARS-CoV-2 specific IgM and IgG levels. In summary, pLV-S pseudotyped virus provides a valid screening tool for the presence of anti SARS-CoV-2 specific neutralizing antibodies in convalescent patient serum.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>33154514</pmid><doi>10.1038/s41598-020-76135-w</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2045-2322
ispartof Scientific reports, 2020-11, Vol.10 (1), p.19076-19076, Article 19076
issn 2045-2322
2045-2322
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7645753
source Open Access: PubMed Central; Publicly Available Content Database; Free Full-Text Journals in Chemistry; Coronavirus Research Database; Springer Nature - nature.com Journals - Fully Open Access
subjects 631/326
631/326/596
692/308/2778
Animals
Antibodies, Neutralizing - blood
Antibodies, Neutralizing - immunology
Antibodies, Viral - blood
Antibodies, Viral - immunology
Betacoronavirus - immunology
Cell Line
Cell lines
COVID-19
Genetic Vectors - genetics
Glycoproteins
Humanities and Social Sciences
Humans
Immunoglobulin G
Immunoglobulin M
Lentivirus - genetics
Mammalian cells
multidisciplinary
SARS-CoV-2
Science
Science (multidisciplinary)
Serologic Tests - methods
Severe acute respiratory syndrome coronavirus 2
Spike glycoprotein
Spike Glycoprotein, Coronavirus - genetics
Spike Glycoprotein, Coronavirus - immunology
Stomatitis
Transduction, Genetic
title Effective screening of SARS-CoV-2 neutralizing antibodies in patient serum using lentivirus particles pseudotyped with SARS-CoV-2 spike glycoprotein
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T15%3A38%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effective%20screening%20of%20SARS-CoV-2%20neutralizing%20antibodies%20in%20patient%20serum%20using%20lentivirus%20particles%20pseudotyped%20with%20SARS-CoV-2%20spike%20glycoprotein&rft.jtitle=Scientific%20reports&rft.au=Tandon,%20Ritesh&rft.date=2020-11-05&rft.volume=10&rft.issue=1&rft.spage=19076&rft.epage=19076&rft.pages=19076-19076&rft.artnum=19076&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-020-76135-w&rft_dat=%3Cproquest_pubme%3E2458039211%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c474t-1b2f2a8cded559074e4c991ed0a4f96627ef51eb0a17bbeadc7511289c3be78c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2471540665&rft_id=info:pmid/33154514&rfr_iscdi=true